{"name":"Panolos Bioscience","slug":"panolos-bioscience","ticker":"","exchange":"","domain":"","description":"Panolos Bioscience is a biotechnology company focused on the development of innovative therapies. The company's lead candidate, PB101, is currently in Phase 1 clinical trials.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMibkFVX3lxTE16dHdZNl9jdHN3UnlFaUJTbDBCRjdKOWZyQkk2TTBERGFueFJFcThtREw0TnNwajMwMUw0SkVzM0wtMEZjcHJTeEhLMEY5OWxhTm9yUGdMdmplNDRYMXR3aDl1dFVodnBscXRZVUdn0gFyQVVfeXFMTTFFQWNtbHpOYl9BY0d2bDF0a0NrQ21TTDJ0UEdhV3lhRjFZenpoV25SYlBmVzFzaDRYQ25sYUhJSThIYTE5U041RlhqR2lMVmlGLXZZR1JjQ05FNl9VUDVUVnpucTdqcTRscWtvRzlibTZ3?oc=5","date":"2025-12-16","type":"deal","source":"koreabiomed.com","summary":"Syntekabio lands 1st antibody license-out in deal worth up to $1.7 mil. for 5 AI-designed candidates - koreabiomed.com","headline":"Syntekabio lands 1st antibody license-out in deal worth up to $1.7 mil. for 5 AI-designed candidates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxOcFN4WDBHZk4xM2pBMXBiREFzQlk1MUF0ZFhycTd0SWdJLXcybFZhbDdlT0JtVGpPUDhHOFVOQUQwTDlxOG90SnlFUEp5S1Q3RmhMek13NWY5a2I5blptTzdlbE9TaThyYktETHVueTB0RW1jLW9RR2VJSDBOaEZCcHloTGdUVURzbGM1TG40R3hiWkFmVEpELTE3c3hqdVE?oc=5","date":"2023-10-17","type":"trial","source":"Oncology Pipeline","summary":"First phase 1 starters challenge Pluvicto and Revolution | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline","headline":"First phase 1 starters challenge Pluvicto and Revolution | ApexOnco - Clinical Trials news and analysis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}